In Brief: Novo Nordisk's Norditropin
Novo Nordisk's Norditropin: Marketing may begin 21 days following a Feb. 26 D.C. federal appeals court decision to overturn a preliminary injunction granted to Genentech in June against the sale of the human growth hormone. Genentech filed a patent infringement suit against Novo Nordisk and Bio-Technology General (Biotropin) in December after the ITC dismissed the Protropin/Nutropin manufacturer's complaint seeking to bar importation of the companies' hGH products. The same appellate court will decide on Genentech's appeal of the ITC decision. The patent dispute will continue as the case goes to trial in Brooklyn federal court later this year or early next year...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth